KR102084388B1 - 박테리오파지 리신을 이용한 생물막의 예방, 붕괴 및 치료 - Google Patents

박테리오파지 리신을 이용한 생물막의 예방, 붕괴 및 치료 Download PDF

Info

Publication number
KR102084388B1
KR102084388B1 KR1020147034615A KR20147034615A KR102084388B1 KR 102084388 B1 KR102084388 B1 KR 102084388B1 KR 1020147034615 A KR1020147034615 A KR 1020147034615A KR 20147034615 A KR20147034615 A KR 20147034615A KR 102084388 B1 KR102084388 B1 KR 102084388B1
Authority
KR
South Korea
Prior art keywords
streptococcus
biofilm
bacteria
lysine
plyss2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147034615A
Other languages
English (en)
Korean (ko)
Other versions
KR20150039129A (ko
Inventor
레이몬드 슈
로버트 씨. 노윈스키
마이클 위터킨드
바바 칸
지미 로톨로
Original Assignee
콘트라펙트 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 콘트라펙트 코포레이션 filed Critical 콘트라펙트 코포레이션
Publication of KR20150039129A publication Critical patent/KR20150039129A/ko
Application granted granted Critical
Publication of KR102084388B1 publication Critical patent/KR102084388B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/40—Viruses, e.g. bacteriophages
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/50—Isolated enzymes; Isolated proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08—Materials for coatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
    • A61L2202/20—Targets to be treated
    • A61L2202/24—Medical instruments, e.g. endoscopes, catheters, sharps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406—Antibiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2420/00—Materials or methods for coatings medical devices
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020147034615A 2012-05-09 2013-05-09 박테리오파지 리신을 이용한 생물막의 예방, 붕괴 및 치료 Expired - Fee Related KR102084388B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261644799P 2012-05-09 2012-05-09
US61/644,799 2012-05-09
US201261736813P 2012-12-13 2012-12-13
US61/736,813 2012-12-13
PCT/US2013/040340 WO2013170022A1 (en) 2012-05-09 2013-05-09 Biofilm prevention, disruption and treatment with bacteriophage lysin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207005447A Division KR20200023521A (ko) 2012-05-09 2013-05-09 박테리오파지 리신을 이용한 생물막의 예방, 붕괴 및 치료

Publications (2)

Publication Number Publication Date
KR20150039129A KR20150039129A (ko) 2015-04-09
KR102084388B1 true KR102084388B1 (ko) 2020-03-06

Family

ID=49551275

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020147034615A Expired - Fee Related KR102084388B1 (ko) 2012-05-09 2013-05-09 박테리오파지 리신을 이용한 생물막의 예방, 붕괴 및 치료
KR1020237030790A Withdrawn KR20230135161A (ko) 2012-05-09 2013-05-09 박테리오파지 리신을 이용한 생물막의 예방, 붕괴 및 치료
KR1020207005447A Ceased KR20200023521A (ko) 2012-05-09 2013-05-09 박테리오파지 리신을 이용한 생물막의 예방, 붕괴 및 치료
KR1020217030507A Ceased KR20210118980A (ko) 2012-05-09 2013-05-09 박테리오파지 리신을 이용한 생물막의 예방, 붕괴 및 치료

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020237030790A Withdrawn KR20230135161A (ko) 2012-05-09 2013-05-09 박테리오파지 리신을 이용한 생물막의 예방, 붕괴 및 치료
KR1020207005447A Ceased KR20200023521A (ko) 2012-05-09 2013-05-09 박테리오파지 리신을 이용한 생물막의 예방, 붕괴 및 치료
KR1020217030507A Ceased KR20210118980A (ko) 2012-05-09 2013-05-09 박테리오파지 리신을 이용한 생물막의 예방, 붕괴 및 치료

Country Status (16)

Country Link
US (4) US9499594B2 (enExample)
EP (2) EP2846827B1 (enExample)
JP (4) JP6348901B2 (enExample)
KR (4) KR102084388B1 (enExample)
CN (2) CN104780933B (enExample)
AU (3) AU2013259427B2 (enExample)
BR (1) BR112014027818B1 (enExample)
CA (2) CA3187222A1 (enExample)
DK (1) DK2846827T3 (enExample)
ES (1) ES2729123T3 (enExample)
HK (1) HK1212208A1 (enExample)
IL (2) IL235526B2 (enExample)
IN (1) IN2014MN02438A (enExample)
MX (2) MX369056B (enExample)
RU (3) RU2646102C2 (enExample)
WO (1) WO2013170022A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220099319A (ko) * 2021-01-06 2022-07-13 주식회사 리신바이오 신규 재조합 엔도라이신 및 이의 용도

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801521B (zh) 2007-05-14 2015-06-17 纽约州立大学研究基金会 生物膜中细菌细胞内的生理学分散响应诱导
KR20230113404A (ko) * 2012-05-09 2023-07-28 콘트라펙트 코포레이션 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의병용물
RU2725809C2 (ru) 2014-06-26 2020-07-06 Дзе Рокфеллер Юниверсити Лизины ацинетобактеров
CN104805066B (zh) * 2015-05-18 2018-04-24 武汉菲吉乐科生物科技有限公司 一种葡萄球菌裂解酶及其应用
EP3120866A1 (en) 2015-07-24 2017-01-25 Zymetech ehf. Use of marine serine proteases for removal, prevention and inhibition of formation and growth of biofilms
US11103547B2 (en) 2016-02-04 2021-08-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods for disrupting biofilms
ES3036077T3 (en) * 2016-02-19 2025-09-12 Klaus Brandenburg Means and methods for treating bacterial infections
RU2664708C1 (ru) * 2017-06-08 2018-08-21 Сергей Иванович Черныш Способ разрушения и предотвращения образования бактериальных биопленок комплексом антимикробных пептидов насекомых
RU2020128276A (ru) * 2018-02-26 2022-03-29 Контрафект Корпорейшн МОДИФИЦИРОВАННЫЕ ЛИЗИНЫ PlySs2 И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
AU2020244764A1 (en) * 2019-03-22 2021-10-14 Contrafect Corporation Method of treating infective endocarditis
JP2022526624A (ja) * 2019-04-11 2022-05-25 コントラフェクト コーポレイション 骨及び関節の感染を治療及び予防する方法
KR102097128B1 (ko) * 2019-06-19 2020-04-06 서울대학교산학협력단 황색포도상구균 제어에 효과적인 키메릭 엔도라이신 Lys109
CN111019876B (zh) * 2019-12-30 2023-04-28 延安大学 一种铜绿假单胞菌工程菌的构建方法及应用
EP4157306A4 (en) * 2020-05-19 2024-07-03 Contrafect Corporation MODIFIED PLYSS2 LYSINES AND ANTIBIOTIC COMBINATIONS FOR USE AGAINST GRAM-POSITIVE BACTERIA
WO2024007055A1 (en) * 2022-07-05 2024-01-11 The University Of Adelaide Method of production of modified phage and method of treatment using same
WO2024149265A1 (zh) * 2023-01-09 2024-07-18 华中农业大学 细菌裂解酶及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1301645C (en) 1986-10-08 1992-05-26 David Bernstein Method for exposing group a streptococcal antigens and an improved diagnostictest for the identification of group a streptococci
US6264945B1 (en) 1997-10-31 2001-07-24 Vincent A Fischetti Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
US6254866B1 (en) 1997-10-31 2001-07-03 New Horizons Diagnostics Corporation Use of phage associated lytic enzymes for treating bacterial infections of the digestive tract
US20060292135A1 (en) 1997-10-31 2006-12-28 Lawrence Loomis Use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl
US5997862A (en) 1997-10-31 1999-12-07 New Horizons Diagnostics Corporation Therapeutic treatment of group A streptococcal infections
US6248324B1 (en) 1997-10-31 2001-06-19 Vincent Fischetti Bacterial phage associated lysing enzymes for treating dermatological infections
BR9917152A (pt) 1999-02-25 2002-11-26 New Horizons Diagnostics Inc Composição para tratamento terapêutico ou profilático de infecção estreptocócica e método e uso respectivos
US6056955A (en) 1999-09-14 2000-05-02 Fischetti; Vincent Topical treatment of streptococcal infections
US20040213765A1 (en) 2001-07-13 2004-10-28 Vincent Fischetti Use of bacterial phage associated lytic enzymes to prevent food poisoning
AU2003291614A1 (en) 2002-05-17 2004-04-08 New Horizons Diagnostics Corporation Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis
US7569223B2 (en) 2004-03-22 2009-08-04 The Rockefeller University Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions
US7638600B2 (en) 2004-03-24 2009-12-29 The Rockefeller University Lytic enzymes and spore surface antigen for detection and treatment of Bacillus anthracis bacteria and spores
EP1621205A1 (en) * 2004-07-28 2006-02-01 OctoPlus Technologies B.V. Antimicrobial peptides derived from CAP18
RU2402347C2 (ru) * 2004-09-22 2010-10-27 ГлаксоСмитКлайн Байолоджикалз с.а. Иммуногенная композиция
WO2008018854A2 (en) 2005-06-06 2008-02-14 The Rockefeller University Bactiophage lysins for bacillus anthracis
US7582291B2 (en) 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
ATE491026T1 (de) 2005-08-24 2010-12-15 Univ Rockefeller Ply-gbs-lysinmutanten
US20080019956A1 (en) * 2006-07-24 2008-01-24 Manoj Kumar Enzymatic prevention and control of biofilm
US8058225B2 (en) * 2007-08-22 2011-11-15 Hyglos Invest Gmbh Proteins for use in human and animal Staphylococcus infections
AU2009217622A1 (en) * 2008-01-10 2009-09-03 Massachusetts Institute Of Technology Engineered bacteriophages as adjuvants for antimicrobial agents and compositions and methods of use thereof
CA2984933C (en) * 2008-07-03 2020-07-07 The Rockefeller University A chimeric bacteriophage lysin with activity against staphylococci bacteria
CA2739717A1 (en) * 2008-10-10 2010-04-15 Lusomedicamenta, S.A. Antibacterial phage peptides and methods of use thereof
KR101016918B1 (ko) 2009-01-08 2011-02-25 주식회사 인트론바이오테크놀로지 박테리아 특이적 넓은 항균 활성을 갖는 신규한 리신 단백질
JP5779092B2 (ja) 2009-05-01 2015-09-16 株式会社きもと 離型性組成物および表面保護フィルム
EP2338916A1 (en) * 2009-12-23 2011-06-29 Hyglos Invest GmbH Chimeric polypeptides and their use in bacterial decoloniation
CN103080307A (zh) 2010-01-25 2013-05-01 美艾利尔斯卡保罗有限公司 A25噬菌体溶解酶
SG184836A1 (en) * 2010-04-27 2012-11-29 Lysando Ag Method of reducing biofilms
EP2397548A1 (en) * 2010-06-18 2011-12-21 Hyglos Invest GmbH Methods of generating and screening for lytic chimeric polypeptides
US9034322B2 (en) * 2011-04-21 2015-05-19 The Rockefeller University Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
US20140179594A1 (en) * 2011-04-21 2014-06-26 The Rockefeller University Streptococcus bacteriophage lysins for treatment of gram positive bacteria in companion animals and livestock
EP2993181A1 (en) 2011-04-27 2016-03-09 Lysando AG New antimicrobial agents
KR20230113404A (ko) 2012-05-09 2023-07-28 콘트라펙트 코포레이션 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의병용물
EP2835193A1 (en) 2013-08-05 2015-02-11 Refractory Intellectual Property GmbH & Co. KG Refractory ceramic nozzle
CN104073478A (zh) * 2014-06-13 2014-10-01 上海交通大学 杀灭革兰氏阳性菌的酶抗生素及其制备、用途
CN104726439B (zh) * 2015-04-13 2017-11-14 武汉菲吉乐科生物科技有限公司 一种广谱的链球菌裂解酶及其应用
CN104805066B (zh) * 2015-05-18 2018-04-24 武汉菲吉乐科生物科技有限公司 一种葡萄球菌裂解酶及其应用
CN116077630A (zh) * 2015-09-17 2023-05-09 抗非特公司 具有对抗革兰氏阴性菌的活性的溶素多肽

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
APPLIED AND ENVIRONMENTAL MICROBIOLOGY, Vol. 73, No. 1, p. 347-352 (2007)*
Jonathan Edward Schmitz, 박사 학위 논문, Rockefeller University, EXPANDING THE HORIZONS OF ENZYBIOTIC IDENTIFICATION (2011)*

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220099319A (ko) * 2021-01-06 2022-07-13 주식회사 리신바이오 신규 재조합 엔도라이신 및 이의 용도
KR102426421B1 (ko) * 2021-01-06 2022-07-29 주식회사 리신바이오 신규 재조합 엔도라이신 및 이의 용도

Also Published As

Publication number Publication date
US20170127683A1 (en) 2017-05-11
KR20200023521A (ko) 2020-03-04
US11524046B2 (en) 2022-12-13
AU2013259427B2 (en) 2017-12-14
RU2735103C2 (ru) 2020-10-28
CN104780933B (zh) 2020-08-28
ES2729123T3 (es) 2019-10-30
CA2872911C (en) 2023-10-03
KR20230135161A (ko) 2023-09-22
AU2018201736B2 (en) 2020-03-19
MX369056B (es) 2019-10-28
AU2020204014A1 (en) 2020-07-02
JP2022163214A (ja) 2022-10-25
US9499594B2 (en) 2016-11-22
EP2846827A1 (en) 2015-03-18
KR20210118980A (ko) 2021-10-01
JP2020189860A (ja) 2020-11-26
RU2018102796A (ru) 2019-02-22
JP2015521178A (ja) 2015-07-27
US20150111813A1 (en) 2015-04-23
BR112014027818A2 (pt) 2017-08-08
IN2014MN02438A (enExample) 2015-07-10
IL235526B1 (en) 2023-04-01
AU2013259427A1 (en) 2014-12-11
EP2846827A4 (en) 2016-03-02
CA2872911A1 (en) 2013-11-14
JP6348901B2 (ja) 2018-06-27
CN111803620A (zh) 2020-10-23
MX2019012877A (es) 2020-01-14
MX2014013587A (es) 2015-07-06
AU2018201736A1 (en) 2018-04-12
WO2013170022A1 (en) 2013-11-14
HK1208366A1 (en) 2016-03-04
CN104780933A (zh) 2015-07-15
CA3187222A1 (en) 2013-11-14
JP7368018B2 (ja) 2023-10-24
RU2018102796A3 (enExample) 2019-02-22
EP2846827B1 (en) 2019-02-13
DK2846827T3 (da) 2019-05-13
BR112014027818B1 (pt) 2023-03-28
US20230277617A1 (en) 2023-09-07
JP6873939B2 (ja) 2021-05-19
IL269426A (en) 2019-11-28
HK1212208A1 (en) 2016-06-10
RU2014149348A (ru) 2016-07-10
RU2020133461A (ru) 2022-04-12
RU2646102C2 (ru) 2018-03-01
IL235526B2 (en) 2023-08-01
US20190387745A1 (en) 2019-12-26
JP2018087242A (ja) 2018-06-07
KR20150039129A (ko) 2015-04-09
EP3513807A1 (en) 2019-07-24
IL235526A0 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
KR102084388B1 (ko) 박테리오파지 리신을 이용한 생물막의 예방, 붕괴 및 치료
KR102310387B1 (ko) 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물
HK40011560A (en) Biofilm prevention, disruption and treatment with bacteriophase lysin
HK1208366B (en) Biofilm disruption with plyss2 lysin

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250228

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250228

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250228